Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma

Kenji Inoue,1 Mayumi Iwasa,1 Masato Wakakura,1 Goji Tomita21Inouye Eye Hospital, 2Toho University Ohashi Medical Center, Tokyo, JapanBackground: The purpose of this study was to evaluate the effects of benzalkonium (BAK)-free travoprost monotherapy administered for 3 years on intraocular pressure an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inoue K, Iwasa M, Wakakura M, Tomita G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/916ad6add731444f96ec4e62b072a7bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:916ad6add731444f96ec4e62b072a7bc
record_format	dspace
spelling	oai:doaj.org-article:916ad6add731444f96ec4e62b072a7bc2021-12-02T03:36:08ZEffects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma1177-54671177-5483https://doaj.org/article/916ad6add731444f96ec4e62b072a7bc2012-08-01T00:00:00Zhttp://www.dovepress.com/effects-of-bak-free-travoprost-treatment-for-3-years-in-patients-with--a10696https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Kenji Inoue,1 Mayumi Iwasa,1 Masato Wakakura,1 Goji Tomita21Inouye Eye Hospital, 2Toho University Ohashi Medical Center, Tokyo, JapanBackground: The purpose of this study was to evaluate the effects of benzalkonium (BAK)-free travoprost monotherapy administered for 3 years on intraocular pressure and visual field performance.Methods: The intraocular pressure of 76 patients with normal tension glaucoma was monitored every 1&ndash;3 months. A Humphrey visual field test was performed every 6 months after treatment and compared with the results before treatment. Visual field performance was also evaluated by trend and event analysis.Results: Thirty cases discontinued within 3 years. Mean intraocular pressure after 3 years of travoprost treatment (14.1 &plusmn; 2.4 mmHg) was significantly lower than that before treatment (16.8 &plusmn; 2.6 mmHg, P &lsaquo; 0.0001). There was no change in the mean deviation and pattern standard deviation as measured by Humphrey visual field test after 3 years of treatment compared with before treatment. Visual field performance was worse in one patient (2.8%) by trend analysis and five patients (13.9%) by event analysis. Treatment was discontinued in six cases (7.9%) due to the appearance of adverse reactions.Conclusion: BAK-free travoprost monotherapy was effective in reducing intraocular pressure for at least 3 years; however, visual field performance worsened in 2.8%&ndash;13.9% of patients with normal tension glaucoma.Keywords: BAK-free travoprost, intraocular pressure, visual field, trend analysis, event analysisInoue KIwasa MWakakura MTomita GDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1315-1319 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Inoue K Iwasa M Wakakura M Tomita G Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
description	Kenji Inoue,1 Mayumi Iwasa,1 Masato Wakakura,1 Goji Tomita21Inouye Eye Hospital, 2Toho University Ohashi Medical Center, Tokyo, JapanBackground: The purpose of this study was to evaluate the effects of benzalkonium (BAK)-free travoprost monotherapy administered for 3 years on intraocular pressure and visual field performance.Methods: The intraocular pressure of 76 patients with normal tension glaucoma was monitored every 1&ndash;3 months. A Humphrey visual field test was performed every 6 months after treatment and compared with the results before treatment. Visual field performance was also evaluated by trend and event analysis.Results: Thirty cases discontinued within 3 years. Mean intraocular pressure after 3 years of travoprost treatment (14.1 &plusmn; 2.4 mmHg) was significantly lower than that before treatment (16.8 &plusmn; 2.6 mmHg, P &lsaquo; 0.0001). There was no change in the mean deviation and pattern standard deviation as measured by Humphrey visual field test after 3 years of treatment compared with before treatment. Visual field performance was worse in one patient (2.8%) by trend analysis and five patients (13.9%) by event analysis. Treatment was discontinued in six cases (7.9%) due to the appearance of adverse reactions.Conclusion: BAK-free travoprost monotherapy was effective in reducing intraocular pressure for at least 3 years; however, visual field performance worsened in 2.8%&ndash;13.9% of patients with normal tension glaucoma.Keywords: BAK-free travoprost, intraocular pressure, visual field, trend analysis, event analysis
format	article
author	Inoue K Iwasa M Wakakura M Tomita G
author_facet	Inoue K Iwasa M Wakakura M Tomita G
author_sort	Inoue K
title	Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
title_short	Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
title_full	Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
title_fullStr	Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
title_full_unstemmed	Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
title_sort	effects of bak-free travoprost treatment for 3 years in patients with normal tension glaucoma
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/916ad6add731444f96ec4e62b072a7bc
work_keys_str_mv	AT inouek effectsofbakfreetravoprosttreatmentfor3yearsinpatientswithnormaltensionglaucoma AT iwasam effectsofbakfreetravoprosttreatmentfor3yearsinpatientswithnormaltensionglaucoma AT wakakuram effectsofbakfreetravoprosttreatmentfor3yearsinpatientswithnormaltensionglaucoma AT tomitag effectsofbakfreetravoprosttreatmentfor3yearsinpatientswithnormaltensionglaucoma
_version_	1718401683144310784

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma

Ejemplares similares